½ÃÀ庸°í¼­
»óǰÄÚµå
1193051

¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : Á¦Ç°º°, ¸Þ¼Òµåº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2031³â)

Leukapheresis Market By Product, By Method, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 274 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀåÀº 2021³â¿¡ 2¾ï 4565¸¸ ´Þ·¯·Î, 2031³â¿¡´Â 5¾ï 6164¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2022-2031³âÀÇ CAGRÀº 8.6%·Î µî·ÏµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ °³¿ä

  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ÁÖ¿ä ÅõÀÚ Æ÷ÄÏ
  • Porter's Five Forces ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • COVID-19 ¿µÇ⠺м®

Á¦4Àå ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : Á¦Ç°º°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • µð¹ÙÀ̽º
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ÀÏȸ¿ë
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦5Àå ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : ¸Þ¼Òµåº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ¿ø½ÉºÐ¸®¹ý
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º° ºÐ¼®
  • ¸·ºÐ¸®
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ¼±ÅÃÀû ÈíÂø
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦6Àå ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : ¿ëµµº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • Ä¡·á¿ë ¿ëµµ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º° ºÐ¼®
  • Á¶»ç ¿ëµµ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦7Àå ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • Ç÷¾× ¼¾ÅÍ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • º´¿ø
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ±âŸ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦8Àå ¹éÇ÷±¸¼ººÐäÁý¼ú ½ÃÀå : Áö¿ªº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • ºÏ¹Ì
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¹æ½Äº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • À¯·´
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • À¯·´ÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¸Þ¼Òµåº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ¿µ±¹
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¸Þ¼Òµåº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ÀϺ»
      • Áß±¹
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • LAMEA
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¹æ½Äº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ºê¶óÁú
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • LAMEAÀÇ ±âŸ Áö¿ª

Á¦9Àå ±â¾÷ »óȲ

  • ¼­·Ð
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10»çÀÇ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÀï È÷Æ®¸Ê
  • ÁÖ¿ä ¹ßÀü

Á¦10Àå ±â¾÷ °³¿ä

  • Adacyte Therapeutics
  • AllCells, LLC.
  • Asahi Kasei Corporation
  • Charles River Laboratories International, Inc.
  • Cerus Corporation
  • Fresenius Kabi
  • Haemonetics Corporation
  • Macopharma
  • SB-Kawasumi Laboratories, Inc.
  • Terumo BCT, Inc.
KSA 23.03.15

The global leukapheresis market was valued at $245.65 million in 2021 and is projected to reach $561.64 million by 2031 registering a CAGR of 8.6% from 2022 to 2031.

Leukapheresis is a laboratory procedure in which white blood cells are removed from a sample of blood. In this process, blood passes through a machine that takes out white blood cells and returns all other blood cells and plasma back into the bloodstream. In addition, the process includes insertion of two intravenous (IV) lines into body. One IV line removes blood while the other carries cleaned blood back to the body. This procedure takes approximately two to three hours to complete.

The growth of global leukapheresis market is majorly driven by increase in demand for leukapheresis, owing to increase in incidences and prevalence of leukemia. In addition, increase in demand for blood donations and rise in demand for leukopaks in clinical research studies responsible for the market growth. Furthermore, increase in awareness regarding leukapheresis procedures in developed countries such as the U.S. further fuel the market growth. However high cost associated with leukapheresis therapeutics and leukopak and blood transfusion safety in developing countries hinder the market growth. Conversely, increase in demand for leukapheresis in pediatric patients is anticipated to provide lucrative opportunities to the market players. 

The global leukapheresis market is segmented into product, method, application, end user, and region. By product, the market is categorized into devices and disposables. On the basis of method, it is segregated into centrifugation, membrane separation, and selective adsorption. By application, it is classified into therapeutics application and research application. On the basis of end user, it is categorized into blood centers, hospitals, and others. The others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the leukapheresis market analysis from 2021 to 2031 to identify the prevailing leukapheresis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the leukapheresis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global leukapheresis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Devices
  • Disposables

By Method

  • Centrifugation
  • Membrane Separation
  • Selective Adsorption

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Blood Centers
  • Hospitals
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Italy
    • Spain
    • Rest of Europe
    • Germany
    • France
    • UK
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Adacyte Therapeutics
    • AllCells, LLC.
    • Asahi Kasei Corporation
    • Charles River Laboratories International, Inc.
    • Cerus Corporation
    • Fresenius Kabi
    • Haemonetics Corporation
    • Macopharma
    • SB-Kawasumi Laboratories, Inc.
    • Terumo BCT, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Devices
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Disposables
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Centrifugation
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Membrane Separation
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Selective Adsorption
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Therapeutic Applications
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Research Applications
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Blood Centers
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Hospitals
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country

CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Product
    • 8.2.3 North America Market size and forecast, by Method
    • 8.2.4 North America Market size and forecast, by Application
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Product
      • 8.2.6.1.2 Market size and forecast, by Method
      • 8.2.6.1.3 Market size and forecast, by Application
      • 8.2.6.1.4 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Product
      • 8.2.6.2.2 Market size and forecast, by Method
      • 8.2.6.2.3 Market size and forecast, by Application
      • 8.2.6.2.4 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Product
      • 8.2.6.3.2 Market size and forecast, by Method
      • 8.2.6.3.3 Market size and forecast, by Application
      • 8.2.6.3.4 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Product
    • 8.3.3 Europe Market size and forecast, by Method
    • 8.3.4 Europe Market size and forecast, by Application
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Product
      • 8.3.6.1.2 Market size and forecast, by Method
      • 8.3.6.1.3 Market size and forecast, by Application
      • 8.3.6.1.4 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Product
      • 8.3.6.2.2 Market size and forecast, by Method
      • 8.3.6.2.3 Market size and forecast, by Application
      • 8.3.6.2.4 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Market size and forecast, by Product
      • 8.3.6.3.2 Market size and forecast, by Method
      • 8.3.6.3.3 Market size and forecast, by Application
      • 8.3.6.3.4 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Product
      • 8.3.6.4.2 Market size and forecast, by Method
      • 8.3.6.4.3 Market size and forecast, by Application
      • 8.3.6.4.4 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Product
      • 8.3.6.5.2 Market size and forecast, by Method
      • 8.3.6.5.3 Market size and forecast, by Application
      • 8.3.6.5.4 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Product
      • 8.3.6.6.2 Market size and forecast, by Method
      • 8.3.6.6.3 Market size and forecast, by Application
      • 8.3.6.6.4 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Product
    • 8.4.3 Asia-Pacific Market size and forecast, by Method
    • 8.4.4 Asia-Pacific Market size and forecast, by Application
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Market size and forecast, by Product
      • 8.4.6.1.2 Market size and forecast, by Method
      • 8.4.6.1.3 Market size and forecast, by Application
      • 8.4.6.1.4 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Market size and forecast, by Product
      • 8.4.6.2.2 Market size and forecast, by Method
      • 8.4.6.2.3 Market size and forecast, by Application
      • 8.4.6.2.4 Market size and forecast, by End User
      • 8.4.6.3 India
      • 8.4.6.3.1 Market size and forecast, by Product
      • 8.4.6.3.2 Market size and forecast, by Method
      • 8.4.6.3.3 Market size and forecast, by Application
      • 8.4.6.3.4 Market size and forecast, by End User
      • 8.4.6.4 Australia
      • 8.4.6.4.1 Market size and forecast, by Product
      • 8.4.6.4.2 Market size and forecast, by Method
      • 8.4.6.4.3 Market size and forecast, by Application
      • 8.4.6.4.4 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Product
      • 8.4.6.5.2 Market size and forecast, by Method
      • 8.4.6.5.3 Market size and forecast, by Application
      • 8.4.6.5.4 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by Product
      • 8.4.6.6.2 Market size and forecast, by Method
      • 8.4.6.6.3 Market size and forecast, by Application
      • 8.4.6.6.4 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Product
    • 8.5.3 LAMEA Market size and forecast, by Method
    • 8.5.4 LAMEA Market size and forecast, by Application
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Product
      • 8.5.6.1.2 Market size and forecast, by Method
      • 8.5.6.1.3 Market size and forecast, by Application
      • 8.5.6.1.4 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Product
      • 8.5.6.2.2 Market size and forecast, by Method
      • 8.5.6.2.3 Market size and forecast, by Application
      • 8.5.6.2.4 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Product
      • 8.5.6.3.2 Market size and forecast, by Method
      • 8.5.6.3.3 Market size and forecast, by Application
      • 8.5.6.3.4 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Product
      • 8.5.6.4.2 Market size and forecast, by Method
      • 8.5.6.4.3 Market size and forecast, by Application
      • 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 Adacyte Therapeutics
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 AllCells, LLC.
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Asahi Kasei Corporation
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Charles River Laboratories International, Inc.
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Cerus Corporation
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Fresenius Kabi
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Haemonetics Corporation
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Macopharma
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 SB-Kawasumi Laboratories, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 Terumo BCT, Inc.
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦